Prof. Herbie Newell awarded CBE in New Year's Honours List

Professor Herbie Newell was awarded a CBE for services to medical research and drug development in the New Year's Honours list for 2019. Prof. Newell was the founding scientific director of the Northern Institute for Cancer Research as well as the director of Translational Research at Cancer Research UK from 2006-2009. 

Prof. Newell was involved in the development of registered cancer treatments carboplatin, commonly used for ovarian and lung cancer, and ralitrexed for bowel cancer. More recently, Prof. Newell was the lead pharmacologist on the team which, based in Newcastle, discovered and helped develop the first-in-class PARP inhibitor rucaparib for ovarian cancer which was recently licensed by the European Medicines Agency and the US equivalent.

Emeritus Professor Herbie Newell, CBE, Newcastle University said: "I feel extremely honoured to be made a CBE; however, this award is not about me.  This honour recognises the wonderful work of the charities that support our research, especially Cancer Research UK, the patients who have taken part in the clinical trials on the drugs I have helped to develop, and all the excellent colleagues in academia and industry I have had the privilege of working with over the years.  This honour also recognises the outstanding quality of the medical research conducted at Newcastle University, and the strengths of our research teams."

Last modified: Wed, 05 Feb 2020 13:13:38 GMT